Human trial: Popular diabetes drug shown to lower inflammation, which may protect the heart
Individuals taking the drug saw a significant drop in inflammatory cell clumps within just two weeks, and the reduction grew even stronger by week 12.
Innovation Catalyst Award
Team: The project will be jointly led by Dr. Robb Flynn (VUMC; MPI), expert in liver disease, metabolic effects of weight loss, and clinical studies; Dr. Jamey Young (VU; MPI), developer of the…
Endocrine Society selects Rafael Arrojo e Drigo among its 2027 Laureate Award winners
Rafael Arrojo e Drigo, PhD, of Vanderbilt University, received the Richard E. Weitzman Outstanding Early Career Investigator Award, which recognizes an exceptionally promising young clinical or…
Protein clues in the blood may help children avoid diseases later in life
Study identifies early signs of cardiovascular-kidney-metabolic disease in children that potentially can be reversed with a new class of weight loss drugs used widely by adults.
Researchers identify new therapeutic target for salt-sensitive hypertension
The Vanderbilt Health team, including members of the Kirabo Lab, discovered that a signaling pathway called AP-1 complex links dietary sodium to immune-driven salt-sensitivity of blood pressure,…